Alerta

METHODS FOR MONITORING IMMUNE STATUS OF A POPULATION

Resumen de: US20260126442A1

The present invention relates to methods for monitoring the immune status of a population by detecting and/or quantifying antibodies present in wastewater. The invention further provides methods and kits for monitoring the presence of an antibody to SARS-CoV-2 or a variant thereof within a population by detecting and/or quantifying SARS-CoV-2-specific antibodies in wastewater.

TREATMENT USING A ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

Resumen de: US20260124293A1

0000 The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

IMMUNOGENIC COMPOSITIONS AGAINST THE OMICRON VARIANT OF SEVERE ACUTE RESPITORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

Resumen de: US20260124294A1

The present invention relates to immunogenic compositions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to immunogenic compositions having recombinant SARS-CoV-2 S proteins derived from Omicron subvariants.

COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: US20260125483A1

The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV. The compositions include antibodies targeting the IL-6 receptor complex, antibodies targeting CD3, dactinomycin, and combinations thereof. The methods of treatment include administration of antibodies and combination therapies to reduce or eliminate symptoms associated with coronavirus infection or pulmonary inflammatory disease.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: AU2024367811A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

USE OF LIPID NANOPARTICLES AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER

Resumen de: US20260124295A1

Disclosed are methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI). The methods comprise administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein, and administering an ICI to the subject, where the composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI. In some aspects, the methods comprising administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens, and administering an ICI to the subject where the composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI.

Substituted Pyrazolo3,4-bpyridine Compounds and Methods of Use Thereof

Resumen de: US20260125399A1

present disclosure relates, in part, to SARS-CoV-2 papain-like protease (PLpro) inhibitors of Formula (I), pharmaceutical compositions thereof, and methods of using the same for promoting an antiviral effect in a subject and/or treating, preventing, and/or ameliorating a viral infection in a subject:

SALT FORM OF PEPTIDE HAVING ANTIVIRAL ACTIVITY

Resumen de: WO2026094984A1

Provided, as an anti-SARS-CoV-2 peptide drug, is an optimal salt form of a peptide that binds to a receptor-binding domain (RBD) in SARS-CoV-2.　A sodium or potassium salt of a peptide according to the present invention has, in a direction from an N-terminus to a C-terminus, a first region including a first helix and a second region including a second helix. The first region and the second region each include a site that binds to a receptor-binding domain (RBD) in SARS-CoV-2. A bond is formed between amino acid residues within five residues on the N-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the first region and amino acid residues within five residues on the C-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the second region, and the peptide binds to the receptor-binding domains (RBD) in SARS-CoV-2.

SARS-COV-2 PROTEIN EPITOPES AND USE THEREOF IN PREVENTION AND DIAGNOSIS OF CORONAVIRUS INFECTIONS

Resumen de: WO2025005816A1

The subject of the invention are novel peptides derived from SARS-CoV-2 coronavirus proteins, the peptides being immunoreactive epitopes that interact with convalescent serum, use thereof in prevention and diagnosis of SARS-CoV-2 infections, and an innovative SARS-CoV-2 vaccine, comprising immunoreactive peptides and a thermostable nanoadjuvant that enables effective intranasal administration.

SARS-COV-2 RNA VACCINES AND USES THEREOF

Resumen de: AU2024308310A1

The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.

Methods for the prophylaxis and treatment of COVID and COVID-19

Resumen de: GB2644651A

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and/or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

HYALURONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4737486A1

0001 The present invention relates to a hyaluronic acid derivative as shown in formula I, and a preparation method thereof and the use thereof in the preparation of an anti-infection drug. The structure of the compound or the pharmaceutically acceptable salt thereof of the present invention is significantly different from that of commercially available hyaluronic acid substances such as TCIsHA and R&D HA, and the compound or the pharmaceutically acceptable salt thereof can form a molecular structure recognized by HepSS-1. The molecule with the new structure can achieve an anti-infection effect by means of inhibiting the binding of SARS-Cov-2 spike protein to ACE2 of a host cell, and is less likely to cause serious adverse reactions clinically, such as bleeding and thrombocytopenia, as compared with heparin.

HIGHLY PURIFIED EICOSAPENTAENOIC ACID, AS FREE FATTY ACID FOR TREATMENT OF CORONAVIRUS-19 (COVID-19)

Resumen de: WO2021191676A1

This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.

THERAPEUTIC DRUG COMBINATIONS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: US20260115164A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided.

SYSTEMS, DEVICES AND METHODS FOR TREATING POST-INFECTION SYMPTOMS OF COVID-19 USING VESTIBULAR NERVE STIMULATION

Resumen de: US20260115456A1

0000 A method for alleviating post-infection symptoms of COVID-19 in a subject employs vestibular nerve stimulation (VeNS). Upon or after onset of symptoms, an electrode is placed into electrical contact with the subject proximate to a location of the subject's vestibular system. A current source delivers VeNS to the electrode in a sequence of current pulses at a subsensory frequency for a treatment session of approximately 30 minutes to approximately 60 minutes to alleviate post-COVID-19 symptoms including fatigue, malaise, headache, and difficulty concentrating.

7-АМINO-1,2,4TRIAZOLO1,5-АPYRIMIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTBALE SALTS THEREOF HAVING ANTIVIRAL AND ANTIMICROBIAL ACTIVITY

Resumen de: WO2026089632A1

The invention relates to pharmaceutically active viperin activator compounds having antiviral and antimicrobial activity and the use thereof, as well as to a pharmaceutical composition and a treatment method using said compounds. More particularly, the invention relates to a compound which is a 7-amino-1,2,4triazolo1,5-аpyrimidine derivative, having the general formula (I), where R1 is AlkS, AlkSO, AlkSO2, COOAlk, CON(Alk)2, substituted or unsubstituted Ph, benzyl, furyl, pyridyl; R2 is Н, Alk, Ph; R3 is ОН, OAlk, NHOAlk, NAlk2, or a saturated 6-membered nitrogen-containing heterocyclic ring bound by a nitrogen atom to a carbonyl group and optionally having a second heteroatom in the ring, selected from among X, where X is О, S, NMe; and Alk is Н, Me, Et, Pr or i-Pr, as well as to a pharmaceutically acceptable salt, solvate or hydrate of said compound. The compounds are intended for the treatment and/or prophylaxis of diseases caused by viral and/or microbial infections, such as, for example, diseases caused by influenza, ARI and SARS-CoV-2 viruses, or by ESKAPE group pathogens.

SARS-CoV-2 Monoclonal antibodies against SARS-CoV-2 and hybridoma cell line producing the same

Resumen de: KR20260058252A

본 발명은 SARS-CoV-2 바이러스에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포주에 관한 것이다.

A METHOD OF PROVIDING PEPTIDES

Resumen de: EP4733768A2

0001 A method of identifying stable peptides from a protein, said method comprising: obtaining a peptide from a protein; comparing a solvent-accessible surface area (SASA) of the peptide with a SASA of a corresponding peptide region within the protein; using a result of the comparison to determine whether or not the peptide is structurally stable relative to the corresponding peptide region within the protein. Also disclosed is use of the method to identify stable immunogenic epitopes of SARS-CoV-2, and methods of detecting an antibody response.

METHOD OF DETECTING SARS-COV-2

Resumen de: WO2024263910A1

Provided is method of detecting SARS-CoV-2 in a sample, including amplifying polynucleotides in the sample to form subgenomic amplicons using a forward subgenomic primer and a reverse subgenomic primer, wherein the forward subgenomic primer hybridizes to a forward subgenomic primer target of a subgenomic SARS-CoV-2 N protein transcript or its complement and the reverse subgenomic primer hybridizes to a reverse subgenomic primer target of the subgenomic SARS-CoV-2 transcript or its complement, and detecting an amount of hybridization of a subgenomic SARS-CoV-2 transcript probe to the subgenomic amplicons, wherein the subgenomic SARS-CoV-2 transcript probe hybridizes to a probe target of the subgenomic amplicons, wherein the probe target of the subgenomic amplicons includes at least a portion of a leader sequence, a transcriptional regulatory sequence, and at least a portion of a junction region between the transcriptional regulatory sequence and a coding sequence of the subgenomic SARS-CoV-2 transcript and the probe target is between the forward subgenomic primer target and the reverse subgenomic primer target

--2 ORF3a Modified SARS-CoV-2 ORF3a polypeptides and uses thereof

Resumen de: KR20260056047A

본 발명은 변형된 사스-코로나바이러스-2(SARS-CoV-2) 항원 ORF3a 폴리펩타이드에 관한 것이며, 상기 ORF3a 폴리펩타이드는 특정 위치의 아미노산을 치환함으로써 구조 안정성을 더욱 향상시킨 변형된 SARS-CoV-2 ORF3a 폴리펩타이드이다. 본 발명은 와일드 타입의 SARS-CoV-2 및 현존하는 SARS-CoV-2 변이주뿐만 아니라 향후 출현가능한 SARS-CoV-2 변이주에까지 대응할 수 있는 상기 변형된 SARS-CoV-2 ORF3a 폴리펩타이드 및 SARS-CoV-2 범용 항원 Spike 폴리펩타이드를 유효성분으로 포함하는 SARS-CoV-2 감염증 예방 또는 치료용 약학적 조성물, 백신 조성물 및 면역원성 조성물을 제공한다.

HLA CLUSTERS, GLOBAL FREQUENCIES, & BINDING ACROSS SARS-CoV-2 VARIATION

Resumen de: US20260112446A1

0000 Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: US20260109734A1

0000 The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF

Resumen de: US20260109684A1

0000 Quinoline compounds are disclosed that have a formula represented by the following; and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as compositions, e g., pharmaceutical compositions, or as dosage forms, e.g., pharmaceutical dosage forms, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases related to RAGE activity.

SARS-COV-2 MPRO INHIBITORS AND USES THEREOF

Resumen de: US20260109672A1

This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS-CoV-2 and related viruses.

VACCINE ADJUVANTS AND FORMULATIONS THEREOF

Nº publicación: WO2026085355A1 23/04/2026

Solicitante:

THE REGENTS OF THE UNIV OF CALIFORNIA [US]
CARSON DENNIS A [US]
COTTAM HOWARD B [US]
HAYASHI TOMOKO [US]
SHUKLA NIKUNJ [US]
CHAN MICHAEL [US]

Resumen de: WO2026085355A1

The present disclosure pertains to the field of vaccine technologies, with a focus on improved vaccine adjuvants and their formulations for enhancing immune responses. The described approach addresses limitations of traditional adjuvants by introducing novel formulations of the TLR7 agonist 1 V270, either as a standalone agent or in combination with co-adjuvants such as 2G272 and 2E151. These formulations include self-assembling nanoparticles, lipid-incorporated nanoparticles, and aqueous or liposomal combinations, designed to enhance antigen-specific immune responses while maintaining favorable safety and stability profiles. Notable advantages include balanced Thl/Th2 immune responses, dose¬ sparing effects, cross-reactive immunity, and compatibility with modern vaccine platforms such as mRNA vaccines. Applications encompass systemic and mucosal immunization against a wide range of pathogens, including influenza, SARS-CoV-2, and other infectious diseases. The described approach demonstrates enhanced immunogenicity, durability, and efficacy, particularly in aged populations and those requiring heterologous prime-boost regimens.